Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of SD-101 Cream in Epidermolysis Bullosa Extension Study
NCT02090283Phase 2Terminated
- Sponsor
- Scioderm
- Start
- Mar 2014
- Primary completion
- Sep 2018
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of allantoin in epidermolysis bullosa (EB), sponsored by Scioderm. Started Mar 2014; status: terminated.
02
Drugs
allantoin
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT02090283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02090283.